GEN ID Lab Services Inc. Announces Preparation to Begin DNA Testing.

FONTANA, Calif. -- GEN ID Lab Services Inc. ("GEN ID") (OTC:GDLB) announced today that as GEN ID nears the release date of its proprietary software, pursuant to its strategic alliance agreement with Advanomics Corp., Advanomics is ready to provide GEN ID the support services and access to the Advanomics labs required to facilitate the Single Nucleotide Polymorphism ("SNP") testing. GEN ID's proprietary software is designed to analyze DNA test results faster, more accurately, for a less expensive cost than is currently being done.

Advanomics' highly skilled technical staff is ready to receive patient samples and to perform the in-house testing of SNP's analysis, according to the GEN ID specifications and through the use of the GEN ID proprietary software. GEN ID will send blood samples taken by physicians directly to the Advanomics lab, where Dr. Steve Slilaty and his staff will extract DNA from the patient's blood sample, conduct SNP testing and analyze the data, all under one roof. Through the agreement between GEN ID and Advanomics, the SNP tests will be faster and less expensive to administer, which in essence makes the SNP test more affordable to a wider population.

Advanomics labs are able to perform SNP analysis and to submit SNP results to the National Institute of Health ("NIH") database, which is the world's most comprehensive database of single nucleotide polymorphisms, in record time.

The present SNP database at the NIH is comprised of six general classes of candidate SNP identification methods:

1.  Direct DNA Sequencing;
2.  Restriction Fragment Length Polymorphism (RFLP);
3.  Single-Stranded Conformational Polymorphism (SSCP);
4.  Computational Analysis;
5.  DNA Hybridization (often employing microarray technology); and
6.  Denaturing High-Pressure Liquid Chromatography (DHPLC).

GEN ID is preparing to launch its proprietary software, which specializes in the expedited SNP analysis. The results of SNP analysis provide physicians with a more enlightened choice of drugs. The GEN ID software will not only be the first of its kind to provide a complete breakdown of the genetic DNA, but will also enable doctors to more accurately predict the effectiveness of drugs and different drug protocol treatments for individual patients. GEN ID's software will be a milestone in the field of Pharmacogenomics Analysis.

"We are looking forward to the beginning of our new SNP testing program using our software. Dr. Steve Slilaty and his Advanomics team, with their collective expertise in genetic research, will help GEN ID provide the customized approach to medical treatment that is vastly needed in the United States and abroad," Hector Veron, president and chief executive officer of GEN ID, stated. "GEN ID will be able to perform a complete battery of SNP tests for as little as $700. Through our software and working agreement with Advanomics, we will reach one of the company's milestones immediately. That is providing SNP data and analysis in a relatively fast, economical, and competent manner, under the supervision of highly respected geneticists. Conducting DNA analyses through the GEN ID system will take the guesswork out of prescribing difficult medical protocol for patients. The program's application will result in saving lives and millions of dollars in unnecessary treatment and potential liability issues."

Veron continued: "The pharmaceutical industry will be in a position to develop higher-quality drugs, in a shorter period of time, at a fraction of the cost. The greatest recognizable benefit of our proprietary software will be felt by the public at large. Medications will be far more customized than ever before, and the cost of health care could drop significantly."

About GEN ID:

GEN ID is in the business of providing SNP testing. SNP stands for Single Nucleotide Polymorphism. An SNP is a small genetic change, or variation, that can occur within a person's DNA sequence. This analysis will provide information on genetic predisposition to various diseases, such as different forms of cancer, cardiovascular abnormalities, dermatological diseases, etc. SNP data also allows predicting pharmacodynamic pattern pertinent to individual drugs for individual patients.

This news release may include "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact included or incorporated herein may constitute forward-looking statements. Although GEN ID believes that the forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. The forward-looking statements involve risks and uncertainties that may affect GEN ID's operations and financial performance. Among the factors that could cause results to differ materially are those risks discussed in GEN ID's filings with the Securities and Exchange Commission, including our Annual Reports on Form 10-KSB.

For more information visit the company's Web site: www.Gen-IDLabs.com.